MedTrace Logo

Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)

NCT00000437 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2017-04-20

No results posted yet for this study

Summary

The purpose of this study is to determine the effectiveness of naltrexone (Revia) or matched placebo combined with nicotine patch (Nicotrol) or placebo patch using a 2x2 design in reducing drinking and smoking in patients with both nicotine and alcohol dependence.

Conditions

  • Alcoholism
  • Smoking

Interventions

DRUG

Naltrexone Tablet and Nicotine Patch

DRUG

Naltrexone Tablet and Placebo Patch

DRUG

Placebo Tablet and Nicotine Patch

DRUG

Placebo Tablet and Placebo Patch

Sponsors & Collaborators

  • National Institute on Alcohol Abuse and Alcoholism (NIAAA)

    collaborator NIH

  • The Scripps Research Institute

    lead OTHER

Principal Investigators

  • Barbara Mason, PhD · University of Miam

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1997-09-26
Primary Completion
2005-09-15
Completion
2005-09-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00000437 on ClinicalTrials.gov